FDG-PET/CT用于乳腺癌初始分期及复发检测
本文综述了FDG-PET/CT在乳腺癌初始分期和复发检测中的作用。FDG-PET/CT对检测腋窝外淋巴结及远处转移敏感性高,在临床IIB期及以上初始分期中有用,对复发检测较传统影像更有效。
要点
- FDG-PET/CT对低增殖、低级别及高分化luminal型乳腺癌有局限性,但无论表型或分级均可用于初始分期。
- 初始分期时,FDG-PET/CT从临床IIB期(T2N1或T3N0)开始非常有用;临床IIA期可能有用但证据不足以推荐常规使用;临床I期(T1N0)无附加价值。
- 复发乳腺癌患者中,FDG-PET/CT检测局部区域或远处复发较传统影像更有效,即使肿瘤标志物正常也有效。
核心结论
- FDG-PET/CT可用于乳腺癌初始分期,无论肿瘤表型(luminal、三阴性或HER2+)和肿瘤分级。
- 对复发乳腺癌,FDG-PET/CT检测局部区域或远处复发较传统影像更有效,并可用于已知复发的全身评估及判断复发是否孤立。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- FDG-PET/CT对检测腋窝外淋巴结和远处转移具有高敏感性。
- FDG-PET/CT对低增殖肿瘤、低级别肿瘤和高分化luminal型乳腺癌有一些局限性。
- FDG-PET/CT对浸润性导管癌(非特殊型浸润性癌)表现更好,对浸润性小叶癌分期也有帮助。
- 在复发乳腺癌患者中,FDG-PET/CT较传统影像更有效地检测局部区域或远处复发,无论临床检查、传统影像或肿瘤标志物(CA 15.3或CEA)升高怀疑复发。
- 即使肿瘤标志物正常,PET/CT也有效。
关键数值与推荐
- 初始分期时,FDG-PET/CT从临床IIB期(T2N1或T3N0)开始非常有用。
- 临床IIA期(T1N1或T2N0)患者中FDG-PET/CT可能有用,但证据不够强,不足以推荐该亚组常规使用。
- 临床I期(T1N0)患者中,FDG-PET/CT无附加价值。
临床怎么用
- 原文未据此给出推荐。
局限性
- FDG-PET/CT对低增殖肿瘤、低级别肿瘤和高分化luminal型乳腺癌有一些局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast cancer is the most frequent cancer diagnosed in women worldwide. Accurate baseline staging is necessary to plan optimal breast cancer management. Early detection and staging of recurrence are also essential for optimal therapeutic management. Hybrid FDG-PET/CT imaging offers high sensitivity in detecting extra axillary lymph nodes and distant metastases. Although FDG-PET/CT has some limitations for low proliferative tumors, low-grade tumors and for well-differentiated luminal breast cancer, PET/CT is useful for the initial staging of breast cancer, regardless of tumor phenotype (luminal, triple negative, or HER2+) and of tumor grade. Although FDG-PET/CT performs better for invasive ductal carcinoma (invasive carcinoma of no specific subtype), it is also helpful for staging invasive lobular carcinomas. At initial staging, FDG-PET/CT becomes very useful for staging from clinical stage IIB (T2N1 or T3N0). FDG-PET/CT could be useful in patients with clinical stage IIA (T1N1 or T2N0), but there is not enough strong evidence to recommend routine use in this subgroup. For clinical stage I (T1N0) patients, FDG-PET/CT offers no added value. In patients with recurrent breast cancer, FDG-PET/CT is more effective than conventional imaging in detecting locoregional or distant recurrence, whether suspected by clinical examination, conventional imaging, or elevation of a tumor marker (CA 15.3 or CEA). PET/CT is effective even in the presence of normal tumor markers. PET/CT is also a powerful imaging modality for performing a whole-body workup of a known recurrence and for determining whether or not the recurrence is isolated.
引用
- Groheux D. FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer. Semin Nucl Med. 2022. PMID: 35636977. doi:10.1053/j.semnuclmed.2022.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。